Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma: phase II trial of the European Osteosarcoma Intergroup
| Autor: | C Ruiz de Elvira, Jeremy Whelan, D Ornadel, William P. Steward, R George, M Nooy, Ian Lewis, Robert L. Souhami, J Bridgewater, J. Pringle |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Neutropenia Adolescent Nausea medicine.medical_treatment Bone Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor Mucositis Medicine Humans Doxorubicin Child Cisplatin Chemotherapy Osteosarcoma business.industry Middle Aged medicine.disease Thrombocytopenia Granulocyte colony-stimulating factor Europe Regimen Chemotherapy Adjuvant Anesthesia Child Preschool Feasibility Studies Female medicine.symptom business medicine.drug Follow-Up Studies |
| Zdroj: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 12(9) |
| ISSN: | 0732-183X |
| Popis: | PURPOSE This report describes the toxicity and feasibility of administering doxorubicin (DOX) and cisplatin (CDDP) at 2-week intervals with granulocyte colony-stimulating factor (G-CSF) to patients with osteosarcoma and the compatibility of this regimen with endoprosthetic surgery performed after three cycles. PATIENTS AND METHODS Twenty-four patients with biopsy-proven osteosarcoma were treated with three preoperative cycles of DOX 25 mg/m2/d on days 1 to 3 and CDDP 100 mg/m2 on day 1 with G-CSF 5 micrograms/kg/d on days 4 to 14. Surgery was scheduled at week 6 to be followed by three further cycles of chemotherapy at 2-week intervals. RESULTS Two-week chemotherapy was feasible, but delays and dose reductions only allowed 74% and 78% of the intended dose-intensity of DOX and CDDP to be administered. Thrombocytopenia accounted for 50% of delays. Significant toxicity included neutropenic sepsis, severe mucositis, prolonged nausea and vomiting, and electrolyte disturbances. Twenty-one limb-salvage procedures and one amputation were performed. There were eight episodes of excessive perioperative bleeding. CONCLUSION Intensive 2-week chemotherapy with intercurrent surgery is feasible and allows a greater dose-intensity of chemotherapy to be administered compared with the same regimen administered at 3-week intervals without G-CSF. The toxicity is considerable, but manageable. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|